3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
6
Dermatologic
5
Head & Neck
4
Thoracic
2
Sarcoma
2
Gastrointestinal
2
Breast
2
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
CNS
1
Conditions
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Interventions
Temozolomide
171
Bevacizumab
106
Radiotherapy
87
Radiation
38
Cyclophosphamide
38
Etoposide
34
Carboplatin
34
Magnetic Resonance Spectroscopy
32
Irinotecan
32
Radiosurgery
27
Vincristine
25
pembrolizumab
24
Everolimus
23
Cisplatin
23
Nivolumab
22
Radiotherapy, Intensity-Modulated
19
Isotretinoin
19
Filgrastim
19
Erlotinib Hydrochloride
19
Topotecan
18
Lomustine
17
Vorinostat
16
Doxorubicin
16
Granulocyte Colony-Stimulating Factor
15
sargramostim
14
antineoplaston A10
13
Radiotherapy, Conformal
13
antineoplaston AS 2-1
12
Granulocyte-Macrophage Colony-Stimulating Factor
12
dinutuximab
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
bempegaldesleukin
×
CNS
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts